Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.
EJHaem
; 3(4): 1241-1251, 2022 Nov.
Article
in En
| MEDLINE
| ID: mdl-36467842
Full text:
1
Database:
MEDLINE
Type of study:
Clinical_trials
Language:
En
Journal:
EJHaem
Year:
2022
Type:
Article